Limits...
A patchless dissolving microneedle delivery system enabling rapid and efficient transdermal drug delivery.

Lahiji SF, Dangol M, Jung H - Sci Rep (2015)

Bottom Line: Dissolving microneedles (DMNs) are polymeric, microscopic needles that deliver encapsulated drugs in a minimally invasive manner.However, due to wide variations in skin elasticity and the amount of hair on the skin, the arrays fabricated on the patch are often not completely inserted and large amount of loaded materials are not delivered.Here, we report "Microlancer", a novel micropillar based system by which patients can self-administer DMNs and which would also be capable of achieving 97 ± 2% delivery efficiency of the loaded drugs regardless of skin type or the amount of hair on the skin in less than a second.

View Article: PubMed Central - PubMed

Affiliation: Department of Biotechnology, Yonsei University, 50 Yonsei-ro, Seodaemun-gu, Seoul, 120-749, Korea.

ABSTRACT
Dissolving microneedles (DMNs) are polymeric, microscopic needles that deliver encapsulated drugs in a minimally invasive manner. Currently, DMN arrays are superimposed onto patches that facilitate their insertion into skin. However, due to wide variations in skin elasticity and the amount of hair on the skin, the arrays fabricated on the patch are often not completely inserted and large amount of loaded materials are not delivered. Here, we report "Microlancer", a novel micropillar based system by which patients can self-administer DMNs and which would also be capable of achieving 97 ± 2% delivery efficiency of the loaded drugs regardless of skin type or the amount of hair on the skin in less than a second.

Show MeSH
In vivo images of induced diabetic mice and the effects of insulin after its application using DMN patch, the Microlancer or subcutaneous (SC) injection.(a) Plasma glucose level changes in diabetic mice over a period of 6 h. (b) Plasma insulin concentrations of diabetic mice in each of the groups over time. (c) Insulin labeled FITC signal intensity comparison of Microlancer and (d) patch at 30 min and 1 h post application.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4300505&req=5

f5: In vivo images of induced diabetic mice and the effects of insulin after its application using DMN patch, the Microlancer or subcutaneous (SC) injection.(a) Plasma glucose level changes in diabetic mice over a period of 6 h. (b) Plasma insulin concentrations of diabetic mice in each of the groups over time. (c) Insulin labeled FITC signal intensity comparison of Microlancer and (d) patch at 30 min and 1 h post application.

Mentions: To examine the in vivo delivery efficacy of the Microlancer compared with the DMN patch and with subcutaneous (SC) injection, we measured changes in the blood glucose levels of diabetic mice after the delivery of insulin. Diabetes was induced in the mice, and the mice were shaved at the area of DMN application in order to facilitate a more accurate comparison. DMN arrays containing 0.2 IU insulin were applied onto the skin of the mice, using either the patch or the Microlancer. To compare the DMN delivery efficiency of the Microlancer with that of subcutaneous injection, 0.2 IU of insulin was injected into mice subcutaneously. With the Microlancer, the DMNs were injected 50 μm deep into the skin. The DMN patch was applied over the skin of each mouse and additionally secured with adhesive tape. Unloaded DMNs were used as a negative control, and were inserted into the skin of control mice using the Microlancer. The changes in the plasma glucose levels of diabetic mice 6 h after the application of insulin by each method are shown in Fig. 5a.


A patchless dissolving microneedle delivery system enabling rapid and efficient transdermal drug delivery.

Lahiji SF, Dangol M, Jung H - Sci Rep (2015)

In vivo images of induced diabetic mice and the effects of insulin after its application using DMN patch, the Microlancer or subcutaneous (SC) injection.(a) Plasma glucose level changes in diabetic mice over a period of 6 h. (b) Plasma insulin concentrations of diabetic mice in each of the groups over time. (c) Insulin labeled FITC signal intensity comparison of Microlancer and (d) patch at 30 min and 1 h post application.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4300505&req=5

f5: In vivo images of induced diabetic mice and the effects of insulin after its application using DMN patch, the Microlancer or subcutaneous (SC) injection.(a) Plasma glucose level changes in diabetic mice over a period of 6 h. (b) Plasma insulin concentrations of diabetic mice in each of the groups over time. (c) Insulin labeled FITC signal intensity comparison of Microlancer and (d) patch at 30 min and 1 h post application.
Mentions: To examine the in vivo delivery efficacy of the Microlancer compared with the DMN patch and with subcutaneous (SC) injection, we measured changes in the blood glucose levels of diabetic mice after the delivery of insulin. Diabetes was induced in the mice, and the mice were shaved at the area of DMN application in order to facilitate a more accurate comparison. DMN arrays containing 0.2 IU insulin were applied onto the skin of the mice, using either the patch or the Microlancer. To compare the DMN delivery efficiency of the Microlancer with that of subcutaneous injection, 0.2 IU of insulin was injected into mice subcutaneously. With the Microlancer, the DMNs were injected 50 μm deep into the skin. The DMN patch was applied over the skin of each mouse and additionally secured with adhesive tape. Unloaded DMNs were used as a negative control, and were inserted into the skin of control mice using the Microlancer. The changes in the plasma glucose levels of diabetic mice 6 h after the application of insulin by each method are shown in Fig. 5a.

Bottom Line: Dissolving microneedles (DMNs) are polymeric, microscopic needles that deliver encapsulated drugs in a minimally invasive manner.However, due to wide variations in skin elasticity and the amount of hair on the skin, the arrays fabricated on the patch are often not completely inserted and large amount of loaded materials are not delivered.Here, we report "Microlancer", a novel micropillar based system by which patients can self-administer DMNs and which would also be capable of achieving 97 ± 2% delivery efficiency of the loaded drugs regardless of skin type or the amount of hair on the skin in less than a second.

View Article: PubMed Central - PubMed

Affiliation: Department of Biotechnology, Yonsei University, 50 Yonsei-ro, Seodaemun-gu, Seoul, 120-749, Korea.

ABSTRACT
Dissolving microneedles (DMNs) are polymeric, microscopic needles that deliver encapsulated drugs in a minimally invasive manner. Currently, DMN arrays are superimposed onto patches that facilitate their insertion into skin. However, due to wide variations in skin elasticity and the amount of hair on the skin, the arrays fabricated on the patch are often not completely inserted and large amount of loaded materials are not delivered. Here, we report "Microlancer", a novel micropillar based system by which patients can self-administer DMNs and which would also be capable of achieving 97 ± 2% delivery efficiency of the loaded drugs regardless of skin type or the amount of hair on the skin in less than a second.

Show MeSH